Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients

This study has implications in increasing the efficacy of cancer immunotherapy in MM.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research

Related Links:

ConclusionsThese findings suggest that self-reported driver ’s license data provide a reasonable approximation of BMI, but are less precise than interview- and questionnaire-based methods. Furthermore, the degree of bias is seemingly unaffected by measurement order and time lag, but appears to become more pronounced as BMI itself increases.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Yu-Tzu Tai The treatment of multiple myeloma (MM) has entered into a new era of immunotherapy. Novel immunotherapies will significantly improve patient outcome via simultaneously targeting malignant plasma cell (PC) and reversing immunocompromised bone marrow (BM) microenvironment. B-cell maturation antigen (BCMA), selectively expressed in PCs and a key receptor for A proliferation-inducing ligand (APRIL), is highly expressed in MM cells from patients at all stages. The APRIL/BCMA signal cascades promote the survival and drug resistance of MM cells and further modulate immunosuppressive BM milieu. Impressively, anti...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study retrospectively evaluated patients with CIT treated on institutional romiplostim treatment pathways at 4 U.S. centers. The primary outcome was achievement of a romiplostim response [median on-romiplostim platelet count (Plt) ≥75x109/L and ≥30x109/L above baseline]. Secondary outcomes included time to Plt≥100x109/L and rates of the following: Plt
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Cancers, Vol. 12, Pages 1467: ImmunoPET in Multiple Myeloma—What? So What? Now What? Cancers doi: 10.3390/cancers12061467 Authors: Clément Bailly Benjamin Chalopin Sébastien Gouard Thomas Carlier Patricia Remaud-Le Saëc Séverine Marionneau-Lambot Philippe Moreau Cyrille Touzeau Françoise Kraeber-Bodere Caroline Bodet-Milin Michel Chérel Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ev...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Perspective Source Type: research
Blood Cancer Journal, Published online: 01 June 2020; doi:10.1038/s41408-020-0331-4Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1. Mol Med Rep. 2020 May 27;: Authors: Zhou F, Du C, Xu D, Lu J, Zhou L, Wu C, Wu B, Huang J Abstract Lung cancer is a devastating cancer with high morbidity and mortality. Ubiquitin‑specific protease (USP) is a type of deubiquitinating enzyme (DUB) that has been implicated in numerous cancers, including colorectal, myeloma and breast. In the present study, the expression of USP51 was determined in the lung cancer cell line A549 and cisplatin (a...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Pablo A, Breaud AR, Clarke W Abstract Bone marrow transplantation is used to treat particular types of cancers such as lymphoma, leukemia, and multiple myeloma. Appropriate dosing of busulfan during the preparative phase is critical for a successful allograft; if blood concentrations get too high significant liver toxicity can occur, if blood concentrations are too low, then graft-versus-host disease (GVHD) can develop. Busulfan monitoring in blood allows hospitals with the opportunity to provide individualized medicine to patients and improve overall patient outcome. Liquid Chromatography-Tandem Mass Spec...
Source: Current Protocols in Toxicology - Category: Toxicology Tags: Curr Protoc Toxicol Source Type: research
The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among pat...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Pack Health is participating in a pilot study with the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. For Pack Health, it's the latest in a series of notable partnerships for the Birmingham-based firm. The study intends to use digital coaching to support individuals with multiple myeloma who are undergoing stem cell transplantation.  “We are excited to expand the role of digital coaching to this unique patient population for whom the transplantation…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Publication date: Available online 21 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Samah Fathy Semary, Mahmoud Hammad, Sonya Soliman, Dina Yassen, Marwa Gamal, Doaa Albeltagy, Nayera Hamdy, Sonia Mahmoud
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Immunotherapy | Myeloma | Stem Cell Therapy | Stem Cells | Study | Vaccines